Description
Recombinant antibodies at Miltenyi Biotec
As an innovation-powered company with a commitment to quality and excellence, Miltenyi Biotec applies cutting-edge methods to discover and develop newer and better antibodies to satisfy both market demand and regulatory requirements.
The Miltenyi way of generating best-in-class antibodies and antibody conjugates
At Miltenyi Biotec, we opt for recombinant antibodies, which enable sequence verification and optimization for lot-to-lot consistency, making them superior to hybridoma-based antibodies.
Infusing our unique expertise
Recombinants are the result of combining genetic material from different immunized animals, and using display technologies to screen in-house antibody libraries for the best antibodies. Additional analyses on existing hybridoma-based antibodies can also give rise to sequences contributing to novel recombinants.
Maximizing value for your research
By further re-engineering these antibody sequences, we can precisely control their properties to achieve the following benefits:
reduce undesirable binding to Fc gamma receptors,
- eliminate destabilizing amino acid motifs,
- increase specific bonding affinity for stronger, more accurate targeting, and
- optimize fluorochrome conjugation for brighter and clearer signals.
In a final step, by synthesizing and cloning the resulting gene sequence, we achieve an expression vector that develops a cell line, which in turn produces a special recombinant antibody.
Better science with quality antibodies
Already in 2015, 100 of the world’s leading scientists collectively called for better standards and reproducibility in antibody production, proposing recombinant antibodies to circumvent variability (Baker, M. Reproducibility crisis: Blame it on the antibodies. Nature 521, 274–276 (2015). https://doi.org/10.1038/521274a). Moreover, by applying reverse engineering, which is encouraged by the EU Directive 2016/943 r, Miltenyi Biotec acts “[i]n the interest of innovation and fostering competition…” (§16).
Overview
Clone REA676 recognizes the human, mouse, and rat AKT antigen. AKT is a family of serine/threonine kinases which is also known as protein kinase B (PKB) or related to the A and C kinases (RAC-PK). AKT intricately regulates many cellular functions such as cell growth and proliferation, cell survival, apoptosis, energy metabolism, and resistance to anti-cancer therapeutics. It consists of three isoforms, AKT1, AKT2, and AKT3 (or PKBα, β, and γ). Although these three isoforms are encoded by separate genes, they share a common NH2-terminal pleckstrin homology (PH) domain, a catalytic domain in the middle, and a COOH terminus. The identity of the overall amino acid sequence of the three isoforms is very high (about 80%); however, the COOH terminus and the PH-linker region are more diverse. All three isoforms contain similar phosphorylation/activation sites: threonine 308 (AKT1), 309 (Akt2), and 305 (AKT3) and serine 473 (Akt1), 474 (AKT2), and 472 (AKT3). Phosphorylated or activated AKT regulates many of its cellular functions through the phosphorylation of a series of downstream players.
Additional information: Clone REA676 displays negligible binding to Fc receptors.
